Skip to main content
First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors. Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J., Patel, P. H., Rosen, E. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680300974